Nuvalent, Inc.

Nuvalent, Inc. (NUVL) priced its initial public offering on Jul 30, 2021 at $17.00 per share, within its $16.00–$18.00 range, raising $16.6M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $796M. J.P. Morgan was lead-left underwriter, joined by TD Cowen and Piper Sandler. Simpson Thacher advised the underwriters.

Nuvalent, Inc. is a preclinical-stage biopharmaceutical company, headquartered in Cambridge, Massachusetts, creating precisely targeted therapies for cancer. It focuses on small molecule inhibitors of kinases that have already been clinically validated as targets.

Status

IPO

Ticker

NUVL

Exchange

Nasdaq Global Select

Priced

Jul 30, 2021

IPO price

$17.00

Price range

$16.00–$18.00

Raised

$16.6M

Market cap at IPO price

$796M

First filed

Jul 7, 2021

Underwriters

J.P. Morgan, TD Cowen and Piper Sandler

Underwriters' counsel

Simpson Thacher

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.